Track topics on Twitter Track topics that are important to you
Stirling Ultracold, developer and manufacturer of a new generation of environmentally-friendly Ultra-Low Temperature (ULT) Freezers, has announced a new distribution agreement with VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers.
Athens, Ohio (PRWEB) March 02, 2017
Stirling Ultracold has announced a new distribution agreement with VWR. VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania, is the leading global independent provider of product and service solutions to laboratory and production customers. As part of this agreement, VWR will distribute Stirling’s Ultra-Low Temperature (ULT) freezers to North American commercial, academic and non-profit research customers. Stirling Ultracold will continue to be an innovator, delivering world-class sustainable ULT storage solutions with VWR providing local sales representation, support and logistics.
Stirling Ultracold and VWR launched this new agreement at VWR’s Americas Sales Conference in January. This provided Stirling Ultracold the opportunity to engage and train VWR’s Sales organization. VWR’s Sales organization had the chance to view Stirling Ultracold’s new high-efficiency SU780XLE upright freezer, along with the unique Shuttle™ portable ULT solution for remote clinical trials and biologic drug delivery.
“As an important next step in our growth plan, we’re very pleased to offer our freezer line through the world’s leading independent provider of laboratory solutions,” noted Stirling Ultracold CEO Neill Lane. “In addition to expanding our presence in the North American research community, this new VWR agreement will benefit our ULT freezer customers and make our freezers more easily accessible.”
“Stirling provides a unique and premium product to a number of the industries VWR supports,” stated Mark McLoughlin, SVP and President, Americas Lab and Distribution Services for VWR. “Adding these products to our portfolio will provide our customers with a more sustainable cold storage solution that will lower their total cost of ownership.”
About Stirling Ultracold
Manufactured and developed by Global Cooling, Inc. in Athens, OH, Stirling Ultracold’s ultra-low temperature freezer products feature the industry’s first reliable cooling technology, using the free-piston Stirling engine. This innovation has allowed the company to provide a new generation of environmentally-friendly ULT freezers that achieve stable storage conditions over a wide temperature range. Using less than one third the electric power of standard compressor-based ULT freezers, as confirmed by independent, ENERGY STAR® protocol testing, Stirling Ultracold freezers were also the first in the U.S. to use 100 percent natural refrigerants.
In addition to the Model SU780XLE upright and SU105UE undercounter freezers, Stirling Ultracold offers the easily transportable Shuttle™ Model ULT-25NE, which is the only portable ULT solution for remote clinical trials and biologic drug delivery.
To request information about the Stirling Ultracold SU780XLE or Shuttle Ultra-Low Temperature Freezers, call 740-274-7900 or visit the company’s website at http://www.StirlingUltracold.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/03/prweb14112744.htmNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...